Rheumatoid arthritis and renal light-chain deposition disease: long-term effectiveness of TNF-α blockade with etanercept.

Abstract

A 68-year-old woman diagnosed with erosive rheumatoid arthritis (RA) was treated with intramuscular methotrexate 15 mg weekly and oral prednisone 5 mg daily. A favorable outcome of 6 years was followed by RA flare and nephrotic syndrome (NS). Renal biopsy revealed non-amyloid light-chain deposition disease. Laboratory analysis and bone marrow biopsy excluded monoclonal protein and plasma cell dyscrasia. Addition of subcutaneous etanercept, 25 mg twice weekly allowed rapid control of both arthritis and NS. To date, after over 7-year follow-up, RA is in clinical remission, 24-h albuminuria is consistently below 0.5 g, and serum creatinine is 0.9 mg/dl.

• Authors: Lorenzo Cavagna, Vincenzo Sepe, Francesca Bobbio-Pallavicini, Filippo Mangione, Roberto Caporali, Carlomaurizio Montecucco
• Journal: International urology and nephrology (Int Urol Nephrol) Vol. 43 Issue 3 Pg. 909-12 (Sep 2011) ISSN: 1573-2584 [Electronic] Netherlands
• PMID: 20559723 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Antirheumatic Agents
• Immunoglobulin G
• Immunoglobulin Light Chains
• Receptors, Tumor Necrosis Factor
• Tumor Necrosis Factor-alpha
• Etanercept
• Prednisone
• Methotrexate

Topics

• Aged
• Anti-Inflammatory Agents (therapeutic use)
• Antirheumatic Agents (therapeutic use)
• Arthritis, Rheumatoid (complications, drug therapy)
• Drug Therapy, Combination
• Etanercept
• Female
• Humans
• Immunoglobulin G (therapeutic use)
• Immunoglobulin Light Chains (immunology)
• Methotrexate (therapeutic use)
• Nephrotic Syndrome (complications, drug therapy, immunology, pathology)
• Prednisone (therapeutic use)
• Receptors, Tumor Necrosis Factor (therapeutic use)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)